Veru Stock: A Contrarian Bet Amidst Steep Declines

Biopharmaceutical firm Veru is presenting fresh clinical findings for its drug candidate Enobosarm at the ObesityWeek 2025 conference today. The data focuses on the compound’s use alongside GLP-1 therapies. Despite this potentially positive development, the company’s shares are experiencing a severe downturn, having plummeted nearly 38% over the preceding ten days. The stock is now trading at a level of $2.52.

The newly released clinical results indicate that Enobosarm can mitigate the significant muscle loss often associated with GLP-1 treatments—a well-known challenge in managing obesity. However, this encouraging scientific news arrives at an inopportune moment for the company’s financial standing. Veru recently needed to raise capital, issuing 8.4 million shares at Read more...